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ABSTRACT 
Objective: To evaluate bioavailability (BA) and bioequivalence 
(BE) studies conducted in Turkey between January 2008 and the 
end of June 2014.
Materials and Methods: Data on BA/BE studies  collected 
from databases for 2008-2014 studies of Turkish Medicines and 
Medical Devices Agency  were evaluated in terms of endpoint 
classification (BA/BE), allocation status (randomized/non-
randomized), blinding (open/single blind/double blind), dose 
(single/multiple dose), and interventional group (single group/ 
parallel/cross-over/factorial).
Results: All studies were open, randomized with healthy male 
volunteers, and the majority had a crossover design and a single 
dose. Overall,  670 studies were conducted in Turkey between 
January 2008 and June 2014, while BE (n=631, 94.2%) studies 
formed the major part. All studies conducted between 2008 and 
2010 (n=274) were BE studies. Thirty-nine (5.8% of overall 
studies) BA studies were conducted from 2011 to 2014, including 
13 studies in 2011 (33.3% of overall BA studies), 15 in 2012 
(38.4% of overall BA studies), 6 in 2013 (15.4% of overall BA 
studies) and 5 in 2014 (12.8% of overall BA studies).
Conclusions: Our findings showed that 670 BA/BE studies 
were conducted in Turkey between 2008 and 2014, including 631 
BE and 39 BA studies with gradual increase in the number of both 
types of studies throughout the years.
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ÖZET
Amaç: Türkiye’de 2008 yılı Ocak ayından 2014 yılı Haziran ayı 
sonuna kadar yapılan biyoyararlanım (BY) ve biyoeşdeğerlik (BE) 
çalışmalarının değerlendirilmesi.
Gereç ve Yöntem: BY/BE çalışmalarına dair veriler 
Türkiye İlaç ve Tıbbi Cihaz Kurumu’nun 2008-2014 yılları 
klinik araştırmalar veritabanından derlenmiştir. Çalışmalar son 
nokta sınıflandırması (BY/BE), yerleştirme durumu (randomize/
nonrandomize), körleme (açık etiketli/tek kör/çift kör), doz (tek/
çoklu doz) ve müdahaleli grup (tek grup/paralel/çapraz/faktoryal) 
göz önüne alınarak değerlendirilmiştir. 
Bulgular: Çalışmaların tamamının randomize yerleştirilen 
sağlıklı erkek gönüllülerle ve açık etiketli yapıldığı, çoğunluğunun da 
çapraz tasarımlı olduğu ve tek doz içerdiği belirlenmiştir. Türkiye’de 
2008 yılı Ocak ayından 2014 Haziran ayının sonuna kadar 670 
çalışma gerçekleştirilmiş, bu çalışmaların büyük bir kısmını ise BE 
(n=631, %94,2) çalışmaları oluşturmuştur. 2008-2010 yılları arasında 
yapılan 370 çalışmanın tamamı BE çalışmalarıdır. 2011-2014 yılları 
arasında toplam 39 (%5,8) BY çalışması yapılmış olmakla beraber 
13 çalışma 2011 yılında (BY çalışmalarının toplamda % 33,3’ü), 
15’i 2012 yılında (BY çalışmalarının toplamda % 38,4’ü), 6’sı 2013 
yılında (BY çalışmalarının toplamda %15,4’ü), 5’i ise 2014 yılının 
ilk yarısında (BY çalışmalarının toplamda %12,8’si) yapılmıştır.
Sonuç: Bulgularımız, yapılan 670 çalışma arasında 631 BE ve 
39 BY çalışması bulunduğunu ve yıllar içerisinde çalışma sayısının 
her iki çalışma türünde de kademeli olarak arttığını göstermiştir. 
Anahtar kelimeler: Biyoeşdeğerlik, Biyoyararlanım, Klinik 
araştırmalar,  Türkiye
Introduction 
Measurement of bioavailability (BA) of new drug 
candidates is an essential component of not only the drug 
development process but also the registration files submitted 
to the health authority. On the other hand, demonstration 
of bioequivalence (BE) of the generic with the innovator 
91Toprak et al.
Bioavailability and  bioequivalence studies in TurkeyMarmara Medical Journal 2015; 28: 90-93
(reference) drug product via conduction of a clinical trial in 
healthy volunteers by measuring blood/urine concentrations 
of the active ingredient has been an essential part of generic 
drug portfolio implemented by drug manufacturers [1,2].
BA/BE studies are included within the drug licensing 
process in Turkey and these studies sponsored by local or 
international companies have been conducted in certain 
accredited centers following the approval by the ethics 
committee and the institutional permission.
Conduction of clinical and analytical phases of BA/
BE studies in Turkey is based on definitions included in 
the “Regulation for the Evaluation of Bioavailability and 
Bioequivalence of Pharmaceutical Products” (27 May 
1994/21942) [3] and “Regulation for the Clinical Trials 
on Pharmaceutical and Biological Products” (13 Apr 
2013/28617) [4] promulgated in the Official Gazette of the 
Republic of Turkey.
According to these regulations,  BA is defined as “the 
rate and extent to which the active ingredient or active 
moiety is absorbed from a pharmaceutical form and becomes 
available in the general circulation and thereby at the site 
of action or reflecting biological fluids,  generally serum or 
plasma”, BE is defined as “the state of two products’ being 
pharmaceutically equivalent and their bioavailabilities’ after 
administration in the same molar dose being similar to such 
degree that their effects, with respect to both efficacy and 
safety, are essentially the same”.
The present study was designed to evaluate characteristics 
of BA/BE studies conducted in Turkey in 2008-2014 based 
on data from database of authority in Turkey.
Materials and Methods 
Data on BA/BE studies in 2008-2014 were collected 
from database of Turkish Medicines and Medical Devices 
Agency. BA/BE studies were conducted in four centers 
accredited for clinical (Erciyes University Hakan Cetinsaya 
Center for Good Clinical Practice, Kayseri; Gaziantep 
University FARMAGEN Center for Good Clinical 
Practice, Gaziantep and Ege University Drug Development 
and Pharmacokinetic Research - Application Center 
(ARGEFAR), Izmir) and analytical (Ege University Drug 
Development and Pharmacokinetic Research - Application 
Center (ARGEFAR), Izmir and Novagenix Bioanalytical 
Drug R&D Center, Ankara) phases of BA/BE studies in 
Turkey. Blood/urine drug concentration measurements 
(analytical phase) in the BA/BE studies of which the clinical 
phases are conducted in the above centers might have 
performed in or out of the country.
Studies conducted within 2008-2014 were evaluated in 
terms of endpoint classification (BA/BE), allocation status 
(randomized/non-randomized), blinding (open/single blind/
double blind), dose (single/multiple dose), and interventional 
group (single group/parallel/cross-over/factorial).
The present study was exempt from the requirement of 
ethical approval in relation to its retrospective design.
Statistical Analysis
Descriptive statistics were used to characterize the 
bioequivalence and bioavailability studies identified in the 
national registry. Data are expressed as “mean (standard 
deviation; SD)”, minimum-maximum and percent (%) 
where appropriate.
Results
Sponsors
According to data of BA/BE studies in 2008-2014,  sponsors 
were generally local companies but also foreign companies 
conducted BA/BE studies in accredited centers in Turkey.
Volunteers
Volunteers registered in BA/BE studies are all healthy male 
and female  volunteers. All volunteers were also documented 
to be healthy adults (generally age 18-55 years). According 
to data from four accredited clinical centers in 2013 totally 
14800 healthy volunteers were registered to their volunteer 
pool.
Study design
Generally,  the BE studies were single dose, open label, 
randomized, crossover studies with healthy volunteers. Also 
parallel design studies and multiple dose studies have been 
conducted but the number of that study designs were very 
few. The number of multiple dose studies was totally eight 
during the time period from 2008 to 2014.
According to databases generally,  BA studies have been 
conducted one arm, single dose with healthy volunteers.
Endpoint
Figure 1 shows that overall 670 BA/BE studies were 
conducted in Turkey between 2008 and 2014, of that BE 
(n=631,  94.2%) studies formed  the majority. From 2008-
2010 all were BE studies, while a total of 39 (5.8%) BA 
studies were conducted in 2011, 2012, 2013, and 2014 
(Figures 1 and 2). The number of BE studies per year was 
96 in 2008, 81 in 2009, 97 in 2010, 96 in 2011, and 90 in 
2012, 130 in 2013, and 41 in the first half of 2014 (Figure 
1). There were 13 BA studies in 2011, 15 in 2012, 6 in 2013, 
and 5 in the first half of 2014. Most of the studies included 
in this study are completed.
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Figure 1. Distribution of bioavailability/bioequivalence studies 
according to years. 
Figure 2. Distribution of studies according to the study endpoint 
(bioavailability/bioequivalence)
Discussion
Evaluation of the database of BA/BE studies conducted 
between 2008 and 2014 in Turkey revealed that a total of 
670 studies (94.2% were BE studies) were conducted in 
Turkey in this six and a half year period. Conduction of  BA 
studies (n=39) started in 2011 with 13(33.3%) studies and 
continued in 2012 with 15 (38.4%) studies, in 2013 with 6 
(15.4%) studies, and in 2014 with 5(10.9%) studies in the 
first half of the year. The number of BE studies was around 
90 per year, it raised to 130 in 2013.
In a recent analysis of all BA and BE studies registered 
in the United States Clinical Trials.gov registry from late 
2007 through 2011 [2], it was determined that over this 
period, more than 2300 interventional BA/BE studies were 
registered. Overall, 47 of 227 (21.0%) ongoing studies 
and 418 of 2161 (19.0%) completed studies were BA 
studies, while 108 of 227 (48.0%) ongoing studies and 
1270 of 2161(59.0%) completed studies were BE studies. 
Randomized studies composed 76% and 90% and open 
studies 62.0% and 81.0% of ongoing and completed studies, 
respectively. Studies with a crossover design composed 
30.0% and 79.0% and with participants from both genders 
composed 82.0% and 75.0% of ongoing and completed 
studies, respectively [2].
According to our findings most of the studies registered 
in the national database 2008-2014 were open label, 
randomized and completed studies with a crossover design 
including participants from males. Selection of only healthy 
volunteers in BA/BE studies registered in database in Turkey 
is in line with the recommendation that BA/BE studies 
should normally be performed with healthy volunteers to 
minimize variability and permit detection of differences 
between pharmaceutical products [5].
Notably, given that most of the studies included in the 
present database were completed BA/BE studies, it should 
be noted that in US registry, ongoing BA/BE studies were 
reported to be more likely to have larger sample sizes, to 
be in later phase clinical trials, to be double-blinded and 
less likely to be cross-over trials, to have higher proportion 
of trials that primarily involved research on treatments 
and enrolled children, while lesser proportion of trials that 
exclusively recruited male participants [2].
Accordingly, to increase inpatient bed availability and 
the number of responsible healthcare personnel, to expand 
pool of healthy volunteers and to increase the number of 
analytical centers along with improving analysis capacity 
of active centers via providing new devices   are amongst 
the targeted strategies of clinical and analytical centers 
accredited for conduction of BA/BE studies in Turkey.
Conclusion
In conclusion, our findings related to evaluation of the 
database of BA/BE studies conducted between 2008 and 
2014 in Turkey revealed conduction of 670 studies including 
631 BE and 39 BA studies with increase in the number 
within a six and a half year period. Revealing data on the 
characteristics of BA/BE studies conducted from 2008 to 
2014 in Turkey, our findings provide insight considering 
current status of BA/BE studies in Turkey and form a basis 
for future research in this area in relation to healthcare policy 
and research priorities.
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